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The changing age structure of the population, the rapid
developments of the pharmaceutical industry, and rising
medicine costs necessitate a review of the Finnish policy
on medicines, including the drug reimbursement system,
in light of new knowledge. 
In its present form, our health care services are total-
ly dependent on medicines, which are the most frequent
means of treating illnesses and symptoms. Medicines do,
however, constitute only one of many cost items adding
up to the sum total of health care expenditure. While
health care services fall predominantly within the sphere
of the public sector, the pharmaceutical sector consists
mainly of private business. Subvention by the society
does play a significant role through reimbursing medi-
cine costs attributable to out-patient care and hospitals
or other institutions of care. 
Although there are many professional and business
interest groups in the pharmaceutical sector, their com-
mon objective is to provide the best available medical
therapy for the patient. The views on the best means to
achieve that objective differ, however, as far as drug pre-
scribing, distribution, financing and reimbursement sys-
tems are concerned.
Despite pressure from multiple sources, we must en-
sure that individual interests will not threaten the soci-
ety’s main objectives under its policy on medicine. These
objectives include the efficacy, safety and quality of the
best medicines for the patient. While its important to
create favourable conditions for developing new medi-
cines, it is also essential to ensure that medicines are
available at the same prices nationally and regionally.
Furthermore, it is important to boost the provision of
non-commercial drug information on medicines both
qualitatively and quantitatively.
Drug reimbursement shall be at a reasonable level
compared with those applicable in countries similar to
Finland. To curb costs, the potential to make use of
generic products should be investigated in order to re-
serve funds to reimburse more expensive new medi-
cines. 
Any reform of the sickness insurance scheme should
be based on the principle that the system guarantees an
equal opportunity for everyone to comply with the drug
therapy prescribed by the physician, regardless of the
patient’s financial position. The pricing and special re-
imbursement systems in respect of medicines shall be
understandable, just and fair to the patient, while treat-
ing service providers equally and being administratively
uncomplicated and logical. Decision shall be objective
and based on verifiable criteria.
The reimbursement system should not be unduly
complicated, the aim being to achieve maximum health
benefits at reasonable costs. Various reimbursement
models should be considered, for instance whether it is
feasible to pay small sums in reimbursement, or should
the reimbursement classes be reduced from three to two.
It can also be asked, whether the prescribing practices
of physicians could be changed by other than the previ-
ously tried means of issuing regulations or instructions.
In spite of the fact that costs will continue to rise in
the future, Finland should, as a Nordic welfare state, be
able to provide high quality medical therapy and health
care in general. The working group appointed by the
Ministry of Social Affairs and Health to consider the
need for reform of the system of reimbursing medicine
costs, is due to give its report on 31 May 2001. In addi-
tion to the issues mentioned above, the working group
shall assess how well the pharmaceutical services pro-
vided by institutions of out-patient care are functioning,
and how the pharmaceutical sector is expected to devel-
op internationally. 
Collaboration is always necessary at preparatory
stages and during the practical implementation of
changes, and that applies also to the policy on pharma-
ceuticals. The best results – in this case the best possible
medical therapy for Finnish patients, and through that a
general improvement in their state of health – can be
achieved by discussing the relevant issues, and taking in-
to consideration different views. 
Maija Perho
Minister for Social Affairs and Health 
Health care and the policy on pharmaceuticals
Editorial
Summary 
Translation Liisa Fellman-Paul
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The aim of pharmacovigilance is to
maintain the level of drug safety by
monitoring the risks involved in
drug therapies and by deciding on
any measures necessary.  By compil-
ing reports on adverse reactions it is
possible to recognise new risks,
which, as their extent is assessed in
relation to the benefits, will finally
result in well-founded measures pro-
moting drug safety.  The register of
adverse reactions based on the com-
pilation of individual reports on ad-
verse reactions has remained the
corner-stone of the entire exercise
since the 1960’s.
Could this register be used for
anything more than detecting
rare signals? 
Would more widely based reporting
practices reveal epidemiological
quantitative information on adverse
reactions?
The entire concept of adverse re-
actions is problematical not only in
the philosophical sense, but in prac-
tice as well.  People constantly expe-
rience various changes in their con-
dition. Only a very few of the symp-
toms which we in everyday language
call adverse reactions of drugs are
such that they could occur solely in
association with the use of a drug.
In that respect we are mainly limited
to confirmed immunological adverse
effects associated with a specific an-
tibody against a certain molecular
structure. Usually, our conclusion
that a drug has caused a change in a
person’s condition (an adverse ef-
fect) is based only on intuitive rea-
soning that the sequence of events in
time would imply a causal connec-
tion (post hoc, ergo propter hoc).
Strictly speaking, generally there is
no ”direct” confirmation of a causal
connection.
The causal connection which we
imagine is not a simple matter of yes
or no according to Aristotelian logic
but rather it contains other alterna-
tives in that it is a question of coin-
cidence in time, through various
contributory stages finally arriving
at the statement that it was the drug
that ”caused” the event (e.g. erosion
caused by a tablet stuck in the oe-
sophagus, and even then you could
suppose that the thickness of the oe-
sophageal mucosa, differences in
motility etc. would have some ef-
fect). It would be better to consider
this phenomenon on the basis of
fuzzy logic: then all changes in
health are more or less part of ad-
verse drug reactions, some almost
0% (especially if the individual has
not even received the drug, but we
don’t generally know this for sure
either) and some almost 100%. We
don’t get very far either with these
conclusions in each individual case
but the causal connection should be
studied as a more general form of
the expression of statistical proba-
bility.
The above conceptual problem
will result in some interesting per-
spectives associated with the compi-
lation of reports on adverse reac-
tions:
♦ It is impossible, even in theory,
to know the exact number and fre-
quency of adverse reactions and,
therefore, under-reporting is actually
an absurd concept. For example,
studies which, on the basis of a sys-
tematic review of series of cases or
patient records, aim to establish ad-
verse drug reactions causing hospi-
talisation, whether they are carried
out retrospectively or prospectively,
only reveal the researchers’ opinion
based on general medical knowledge
on the proportion of drugs as the
cause of hospitalisation, i.e. nothing
more than an educated guess in the
scientific sense. Even at best, the re-
sult reflects the researchers’ extent
of knowledge, not the true frequen-
cy of adverse reactions.
♦ The more infrequently an ad-
verse event occurs in the population,
the better spontaneous reporting be-
comes as a means of detecting
whether the risk is considerably in-
creased by a certain drug. An exam-
ple: a total of 10–12 cases of aplastic
anaemia are diagnosed annually in
Finland irrespective of cause. If in
any year a suspicion arises of, say,
three or four cases of aplastic
anaemia in the users of drug A, and
the number of users of this drug is,
for example, 1% (50,000), then,
based on such sparse information as
this, we can conclude with fair prob-
ability that this particular drug in-
creases the risk of aplastic anaemia.
What information can be obtained by reports on
adverse reactions?
Erkki Palva
PROFESSOR, RESEARCH DIRECTOR
Drug Information Centre
National Agency for Medicines
A D R  N e w s
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♦ If, on the contrary, the adverse
event under study is prevalent, all
the information gained by reporting
adverse reactions will become diffi-
cult to interpret.  Another example:
about 200,000 cases of gastroin-
testinal haemorrhage occure each
year in Finland irrespective of cause.
One year, say, a total of 8 cases of
suspected haemorrhage is reported
as being caused by drug A and the
number of suspected cases reported
as being caused by drug B is 1. The
number of users of both drugs in
Finland that year was 100,000. Can
we say that A or B increases the risk
of haemorrhage or that A is more
dangerous than B? Of course we
can’t the reason being that, also
quite coincidentally, the number of
cases in user populations of this size
may reach thousands. If we then
consider that the issue will be settled
if all cases are reported, the end re-
sult will also include, in addition to
all the cases ”caused by the drug”,
all those that were associated merely
by chance.
It should be borne in mind that,
in principle, the conceptual contro-
versy is associated with both pro-
spective controlled clinical trials and
non-experimental epidemiological
studies. However, in these studies
the problem is avoided by compiling
information on all adverse events
and then comparing these in the
treated and control patients. We can
then talk about causality if the study
has been done prospectively but in
the case of a non-experimental epi-
demiological study the issue remains
much more uncertain.
In spite of the above problems
we can say that the register of ad-
verse reactions based on sponta-
neous reporting is important and is
often in practice the only feasible
means of discovering rare severe ad-
verse reactions. However, it is very
important to bear its limitations in
mind and to understand at the same
time that widening the area of appli-
cation of this information compiling
system to cover more general ad-
verse events and abolishing the ”un-
der-reporting” will multiply the
amount of information on which no
conclusions can be drawn and which
is easily misinterpreted. Quantitative
information on adverse drug effects
should generally be obtained
through epidemiological studies.
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Liver damage caused by anti-inflam-
matory analgesics is very rare. The
incidence of symptomatic liver dam-
age is estimated at 0.001–0.05%.
Symptom-free, mild increase in he-
patic enzymes is more common and
may occur in as many as 5–15% of
patients. The frequency and the 
pattern of liver damage vary between
the anti-inflammatory analgesics. The 
damage is classified as hepatocellu-
lar, cholestatic or as a mixture of
these. Hepatocellular damage is often
associated with hepatocellular necro-
sis. The levels of hepatic enzymes
(AST, ALT) are considerably in-
creased, whereas the levels of serum
alkaline phosphatase (ALP) and
bilirubin are increased less. In the
case of cholestatic damage the bil-
iary secretion is decreased and the
serum levels of ALP and bilirubin
are increased. The increase in hepat-
ic enzymes may be quite small. The
prognosis of cholestatic damage is
better than that of hepatocellular
damage and the normal situation is
often restored after withdrawal of
medication. The diagnosis of hepati-
tis requires a histological lesion di-
agnosed with the aid of liver biopsy.
The mechanisms of liver damage
caused by anti-inflammatory anal-
gesics are not well known. The reac-
tions may be idiosyncratic, host-de-
pendent and lacking precise correla-
tion with the dose. The damage may
be caused by a reactive/toxic
metabolite formed from the drug.
Sometimes the liver damage may be
associated with symptoms indicative
of hypersensitivity reaction (e.g.
fever, eosinophilia, rash, arthralgia).
The register of adverse reactions
maintained by the National Agency
for Medicines vas received a total of
about 15,200 reports between 1973
and November 2000 on suspected
adverse reactions in association with
the use of drugs. About one thou-
sand (6.6%) of these reports in-
volved a variety of effects on the liv-
er. A total of 59 cases have been re-
ported in association with the use of
anti-inflammatory analgesics where
the patient’s liver was found to have
been adversely affected (Table). The
majority of cases only involved a
change in liver function tests.
Nimesulide
A total of 17 of the reports on ad-
verse effects on the liver were linked
with the use of nimesulide.  Eight of
these cases involved hepatitis and
nine increased hepatic enzyme levels.
The majority of patients (14) were
women. The average age was 61
years (range between 23 and 88
years), and nine of the patients were
over 60 years of age. The symptoms
or findings of liver effects usually
appeared after 1–6 weeks of treat-
ment. In eleven patients’ the labora-
tory values had returned to normal
at the follow-up after nimesulide
was stopped. Six patients had still
not recovered 2–8 weeks after with-
drawal of medication, when the re-
port on the adverse effect was made.
Five patients were using concomi-
tant drugs which have been reported
to have hepatic reactions. According
to published case reports, nimesulide
can cause both hepatocellular necro-
sis and pure cholestasis. Individual
cases of fatal liver damage have also
been reported.
Nimesulide is a relatively new
Hepatic reactions associated with the use of anti-
inflammatory analgesics
Marja-Leena Nurminen
SENIOR MEDICAL OFFICER
Drug Information Centre
National Agency for Medicines
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Hepatic  react ions caused by anti -
inf lammatory analgesics  and in-
cluded in the register  of  adverse
effects  of  the National  Agency
for  Medicines during 1973–No-
vember  2000.
Drug                          Number
Hepat i t is
nimesul ide 8
dic lofenac 3
naproxen 2
acetylsal icyl ic  acid 1
ibuprofen 1
piroxicam 1
Other  l iver  damage 
(no evidence of  hepatit is)
di f lunisal 1
indomethacin 1
Increased hepatic  enzymes 
nimesul ide 9
dic lofenac 8
ibuprofen 5
tol fenamic acid 5
indomethacin 4
ketoprofen 2
acetylsal icyl ic  acid 1
phenylbutazone 1
mefenamic acid 1
meloxicam 1
naproxen 1
oxyphenbutazone 1
piroxicam 1
sul indac 1
t iaprofen acid 1
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drug, introduced on the Finnish
market in January 1998. It is widely
used, however, and the number of
daily doses (0.2 g) by September
2000 totalled over 14 million. One
reason for the popularity of nime-
sulide is probably its selectivity
which, as a COX-2 inhibitor, is
claimed to be higher than that of
older anti-inflammatory analgesics
and the fewer cases of gastrointesti-
nal tract ulcers it causes.
Due to its adverse effects on the
liver, the product information on
nimesulide was updated at the be-
ginning of 2000. Hepatic insufficien-
cy was added to the contraindica-
tions and additional text was includ-
ed in the section on warnings 
according to which patients with 
abnormal values in their liver 
function tests and/or patients with
symptoms indicative of liver damage
(anorexia, nausea, vomiting, jaun-
dice) during nimesulide therapy
must be closely monitored and med-
ication stopped. These patients
should not be re-exposed to nime-
sulide. Increased hepatic enzyme val-
ues were included in rare adverse ef-
fects in the SPC, and cholestatis and
rapidly developing hepatitis were in-
cluded in the list of very rare ad-
verse effects.
Diclofenac
Among anti-inflammatory anal-
gesics, the second largest number of
reports on adverse effects on the liv-
er received by the register on ad-
verse reactions is associated with the
use of diclofenac (11 cases). The av-
erage age of the patients was 53
(varying between 31 and 80 years)
and nine of the patients were
women. According to the reports,
liver values returned to normal in
seven patients after withdrawal of
medication and one case of liver
damage proved fatal. Diclofenac has
been in clinical use since 1977. The
reports on adverse hepatic effects
are distributed rather evenly in the
years between 1978 and 2000. A he-
patic reaction associated with di-
clofenac may not appear until after
several months of treatment. The
liver damage is usually of a hepato-
cellular or mixed type and less than
10 % of cases have features of
cholestatic damage. Predisposition
to the liver damage caused by di-
clofenac appears to increase with
advancing age.
Other anti-inflammatory
analgesics
According to the literature, the use
of sulindac is associated with liver
reactions. The drug is no longer
available on the Finnish market. He-
patic reactions associated with other
anti-inflammatory analgesics cur-
rently in use are very rare. This
would appear to be true also ac-
cording to the reports received by
the register of adverse effects of the
National Agency for Medicines
(Table).
Conclusion
The risk of liver damage associated
with anti-inflammatory analgesics is
very small compared with the symp-
toms of gastric irritation, ulcer and
gastrointestinal haemorrhage that
they cause. Howerer, the risk of he-
patic reactions caused by anti-in-
flammatory analgesics may increase
with age. The risk of liver damage is
also greater in patients on concomi-
tant therapy with some other hepa-
totoxic medication. Patients with
rheumatoid arthritis, for example,
use many drugs which have been as-
sociated with liver damage. These
include, for example, gold salts, sul-
phasalazine, penicillamine, metho-
trexate and ciclosporine. There is no
information based on studies regard-
ing underlying hepatic disorders or
excess consumption of alcohol, but
care should be exercised when treat-
ing these patients.
Translation Mervi Moisander
